君实生物上半年营收11.68亿元 仍未扭亏

Core Insights - Junshi Biosciences reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of approximately 48.64% [1] - The net profit attributable to shareholders was -413 million yuan, an improvement from a net loss of 645 million yuan in the same period last year [1] - The core product, Tuoyi (Tremelimumab), generated sales revenue of 954 million yuan in China, marking a year-on-year increase of about 42% [1] Product and Market Development - Tuoyi is the first domestically developed PD-1 monoclonal antibody to be successfully launched in China and has also entered the U.S. market [1] - As of mid-2025, Tuoyi has received approval for 12 indications in China and has been approved for sale in multiple countries including the U.S., EU, India, and Australia [1] - Junshi Biosciences has submitted or received applications for Tuoyi in various countries including Brazil, Colombia, and South Africa, and has established commercial partnerships in over 80 countries [2] Pipeline and Future Prospects - In addition to Tuoyi, Junshi Biosciences has three other commercialized drugs and nearly 30 drug candidates in clinical trials, with over 20 in preclinical development [2]